Equities

Oxford Biomedica PLC

Oxford Biomedica PLC

Actions
  • Price (EUR)2.24
  • Today's Change0.08 / 3.70%
  • Shares traded0.00
  • 1 Year change-52.14%
  • Beta--
Data delayed at least 15 minutes, as of Mar 28 2024 08:37 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Oxford Biomedica plc is a United Kingdom-based cell and gene therapy research, development and bio-processing company. The Company is engaged in providing services to third parties, as well as performing internal research and development for its own purposes. It performs a range of analytical assays within its in-house quality check (QC) labs. The Company operates through two segments: Platform and Product. Platform segment is involved in bio-processing and processes development activities undertaken process by third parties, which is the partner programme for LentiVector and AAV CDMOs business. The segment also includes internal technology developments and technical intellectual property within the LentiVector platform. Product segment consists of the clinical and pre-clinical development of in vivo and ex vivo cell and gene therapy products (gene therapeutics), which are owned by the Company.

  • Revenue in GBP (TTM)119.02m
  • Net income in GBP-61.63m
  • Incorporated1996
  • Employees891.00
  • Location
    Oxford Biomedica PLCWindrush Court, Transport WayOXFORD OX4 6LTUnited KingdomGBR
  • Phone+44 186 578 3000
  • Fax+44 186 578 3001
  • Websitehttps://www.oxb.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
OXB:LSE since
announced
Transaction
value
ABL Europe SASDeal completed20 Sep 202320 Sep 2023Deal completed-16.77%16.02m
Data delayed at least 20 minutes, as of Mar 28 2024 18:00 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.